GDF15/MIC1 and MMP9 Cerebrospinal Fluid Levels in Parkinson's Disease and Lewy Body Dementia.
Based on animal and ex-vivo experiments, Growth/Differentiation Factor-15 (GDF15, also called Macrophage Inhibitory Cytokine-1, MIC1), a member of the transforming growth factor-beta family, and Matrix Metalloproteinase-9 (MMP9), a member of the matrix metalloprotease family may be potential markers...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2016-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC4777571?pdf=render |
| _version_ | 1811206991392014336 |
|---|---|
| author | Walter Maetzler Willy Deleersnijder Valérie Hanssens Alice Bernard Kathrin Brockmann Justus Marquetand Isabel Wurster Tim W Rattay Lorenzo Roncoroni Eva Schaeffer Stefanie Lerche Anja Apel Christian Deuschle Daniela Berg |
| author_facet | Walter Maetzler Willy Deleersnijder Valérie Hanssens Alice Bernard Kathrin Brockmann Justus Marquetand Isabel Wurster Tim W Rattay Lorenzo Roncoroni Eva Schaeffer Stefanie Lerche Anja Apel Christian Deuschle Daniela Berg |
| author_sort | Walter Maetzler |
| collection | DOAJ |
| description | Based on animal and ex-vivo experiments, Growth/Differentiation Factor-15 (GDF15, also called Macrophage Inhibitory Cytokine-1, MIC1), a member of the transforming growth factor-beta family, and Matrix Metalloproteinase-9 (MMP9), a member of the matrix metalloprotease family may be potential markers for Lewy body disorders, i.e. Parkinson's disease with (PDD) and without dementia (PDND) and Lewy body dementia (DLB). GDF15 has a prominent role in development, cell proliferation, differentiation, and repair, whereas MMP9 degrades, as a proteolytic enzyme, components of the extracellular matrix. In this study, cerebrospinal fluid GDF15 and MMP9 levels of 59 PDND, 17 PDD and 23 DLB patients, as well as of 95 controls were determined, and associated with demographic, clinical and biochemical parameters. Our analysis confirmed the already described association of GDF15 levels with age and gender. Corrected GDF15 levels were significantly higher in PDD than in PDND patients, and intermediate in DLB patients. Within Lewy body disorders, GDF15 levels correlated positively with age at onset of Parkinsonism and dementia, Hoehn & Yahr stage and cerebrospinal fluid t-Tau and p-Tau levels, and negatively with the Mini Mental State Examination. Remarkably, it does not relevantly correlate with disease duration. MMP9 was not relevantly associated with any of these parameters. Cerebrospinal GDF15, but not MMP9, may be a potential marker of and in Lewy body disorders. |
| first_indexed | 2024-04-12T03:57:27Z |
| format | Article |
| id | doaj.art-a84ffd74fe2a4aa0ab4bf46cd7400f86 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-04-12T03:57:27Z |
| publishDate | 2016-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-a84ffd74fe2a4aa0ab4bf46cd7400f862022-12-22T03:48:48ZengPublic Library of Science (PLoS)PLoS ONE1932-62032016-01-01113e014934910.1371/journal.pone.0149349GDF15/MIC1 and MMP9 Cerebrospinal Fluid Levels in Parkinson's Disease and Lewy Body Dementia.Walter MaetzlerWilly DeleersnijderValérie HanssensAlice BernardKathrin BrockmannJustus MarquetandIsabel WursterTim W RattayLorenzo RoncoroniEva SchaefferStefanie LercheAnja ApelChristian DeuschleDaniela BergBased on animal and ex-vivo experiments, Growth/Differentiation Factor-15 (GDF15, also called Macrophage Inhibitory Cytokine-1, MIC1), a member of the transforming growth factor-beta family, and Matrix Metalloproteinase-9 (MMP9), a member of the matrix metalloprotease family may be potential markers for Lewy body disorders, i.e. Parkinson's disease with (PDD) and without dementia (PDND) and Lewy body dementia (DLB). GDF15 has a prominent role in development, cell proliferation, differentiation, and repair, whereas MMP9 degrades, as a proteolytic enzyme, components of the extracellular matrix. In this study, cerebrospinal fluid GDF15 and MMP9 levels of 59 PDND, 17 PDD and 23 DLB patients, as well as of 95 controls were determined, and associated with demographic, clinical and biochemical parameters. Our analysis confirmed the already described association of GDF15 levels with age and gender. Corrected GDF15 levels were significantly higher in PDD than in PDND patients, and intermediate in DLB patients. Within Lewy body disorders, GDF15 levels correlated positively with age at onset of Parkinsonism and dementia, Hoehn & Yahr stage and cerebrospinal fluid t-Tau and p-Tau levels, and negatively with the Mini Mental State Examination. Remarkably, it does not relevantly correlate with disease duration. MMP9 was not relevantly associated with any of these parameters. Cerebrospinal GDF15, but not MMP9, may be a potential marker of and in Lewy body disorders.http://europepmc.org/articles/PMC4777571?pdf=render |
| spellingShingle | Walter Maetzler Willy Deleersnijder Valérie Hanssens Alice Bernard Kathrin Brockmann Justus Marquetand Isabel Wurster Tim W Rattay Lorenzo Roncoroni Eva Schaeffer Stefanie Lerche Anja Apel Christian Deuschle Daniela Berg GDF15/MIC1 and MMP9 Cerebrospinal Fluid Levels in Parkinson's Disease and Lewy Body Dementia. PLoS ONE |
| title | GDF15/MIC1 and MMP9 Cerebrospinal Fluid Levels in Parkinson's Disease and Lewy Body Dementia. |
| title_full | GDF15/MIC1 and MMP9 Cerebrospinal Fluid Levels in Parkinson's Disease and Lewy Body Dementia. |
| title_fullStr | GDF15/MIC1 and MMP9 Cerebrospinal Fluid Levels in Parkinson's Disease and Lewy Body Dementia. |
| title_full_unstemmed | GDF15/MIC1 and MMP9 Cerebrospinal Fluid Levels in Parkinson's Disease and Lewy Body Dementia. |
| title_short | GDF15/MIC1 and MMP9 Cerebrospinal Fluid Levels in Parkinson's Disease and Lewy Body Dementia. |
| title_sort | gdf15 mic1 and mmp9 cerebrospinal fluid levels in parkinson s disease and lewy body dementia |
| url | http://europepmc.org/articles/PMC4777571?pdf=render |
| work_keys_str_mv | AT waltermaetzler gdf15mic1andmmp9cerebrospinalfluidlevelsinparkinsonsdiseaseandlewybodydementia AT willydeleersnijder gdf15mic1andmmp9cerebrospinalfluidlevelsinparkinsonsdiseaseandlewybodydementia AT valeriehanssens gdf15mic1andmmp9cerebrospinalfluidlevelsinparkinsonsdiseaseandlewybodydementia AT alicebernard gdf15mic1andmmp9cerebrospinalfluidlevelsinparkinsonsdiseaseandlewybodydementia AT kathrinbrockmann gdf15mic1andmmp9cerebrospinalfluidlevelsinparkinsonsdiseaseandlewybodydementia AT justusmarquetand gdf15mic1andmmp9cerebrospinalfluidlevelsinparkinsonsdiseaseandlewybodydementia AT isabelwurster gdf15mic1andmmp9cerebrospinalfluidlevelsinparkinsonsdiseaseandlewybodydementia AT timwrattay gdf15mic1andmmp9cerebrospinalfluidlevelsinparkinsonsdiseaseandlewybodydementia AT lorenzoroncoroni gdf15mic1andmmp9cerebrospinalfluidlevelsinparkinsonsdiseaseandlewybodydementia AT evaschaeffer gdf15mic1andmmp9cerebrospinalfluidlevelsinparkinsonsdiseaseandlewybodydementia AT stefanielerche gdf15mic1andmmp9cerebrospinalfluidlevelsinparkinsonsdiseaseandlewybodydementia AT anjaapel gdf15mic1andmmp9cerebrospinalfluidlevelsinparkinsonsdiseaseandlewybodydementia AT christiandeuschle gdf15mic1andmmp9cerebrospinalfluidlevelsinparkinsonsdiseaseandlewybodydementia AT danielaberg gdf15mic1andmmp9cerebrospinalfluidlevelsinparkinsonsdiseaseandlewybodydementia |